![Andy de Deene](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andy de Deene
Corporate Officer/Principal bei
OXURION NV
Profil
Dr. Andy de Deene is a Chief Development Officer at Oxurion NV.
Dr. de Deene was previously employed as a Director & Manager by The Janssen Research Foundation and a Director & Manager by Xcellentis NV.
He received his graduate degree from Universität zu Köln, a graduate degree from Ghent University, an MBA from Vlerick Leuven Gent Management School and a doctorate degree from Ghent University.
Aktive Positionen von Andy de Deene
| Unternehmen | Position | Beginn |
|---|---|---|
| OXURION NV | Corporate Officer/Principal | 01.06.2008 |
Ehemalige bekannte Positionen von Andy de Deene
| Unternehmen | Position | Ende |
|---|---|---|
Xcellentis NV
 Xcellentis NV Pharmaceuticals: MajorHealth Technology Develops clinical stage pipeline products for the treatment of chronic, hard-to-heal wounds | Direktor/Vorstandsmitglied | - |
The Janssen Research Foundation | Direktor/Vorstandsmitglied | - |
Ausbildung von Andy de Deene
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
21
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Universität zu Köln
 Universität zu Köln Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ghent University
 Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vlerick Leuven Gent Management School
 Vlerick Leuven Gent Management School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxurion NV
 Oxurion NV Pharmaceuticals: MajorHealth Technology Develops innovative vascular biopharmaceuticals for the treatment of eye disease, vascular disease and cancer | Health Technology |
Xcellentis NV
Xcellentis NV Pharmaceuticals: MajorHealth Technology Develops clinical stage pipeline products for the treatment of chronic, hard-to-heal wounds | Health Technology |
The Janssen Research Foundation |
Wählen Sie MarketScreener 
